Immunogenicity and safety of acellular pertussis vaccine at birth

出生时无细胞百日咳疫苗的免疫原性和安全性

• 批准号: nhmrc : 570756
• 负责人: A/Pr Nicholas Wood
• 金额: $ 100.62万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/immunogenicity-safety-acellular-vaccine-birth/82512
• 关键词: Immunogenicity; safety; acellular; pertussis; vaccine

Currently, the first dose of a vaccine to protect against pertussis (whooping cough) is not given until 2 months of age, and third dose until 6 months. However, more than 80% of the most severe cases of pertussis (resulting in hospitalisation or death) occur before 6 months. This study aims to show that giving the first dose of pertussis vaccine at birth and the second dose at 6 weeks protects babies at the time they are most likely to die or become severely ill from whooping cough

目前，预防百日咳的第一剂疫苗要到2个月大时才接种，第三剂要到6个月大时才接种。然而，超过80%的最严重的百日咳病例（导致住院或死亡）发生在6个月之前。这项研究旨在表明，在出生时接种第一剂百日咳疫苗，在6周时接种第二剂百日咳疫苗，可以在婴儿最有可能死于百日咳或患上严重百日咳的时候保护婴儿。